Accurate Antibody Testing is Necessary to Reopen the Global Economy May 11, 2020 - Baystreet.ca There’s sizable demand for COVID-19 antibody tests. While the World Health Organization says it’s still too early to tell if having antibodies makes people immune to catching COVID-19, politicians are clamoring for more testing. That’s because if enough people test positive without getting sick, says Fox 11 Los Angeles, “it’s a good indicator that restrictions can start being eased.” “The more testing, the more open the economy,” Gov. Andrew M. Cuomo of New York said, as quoted by the New York Times. “He has pushed for the production of antibody tests as a central cog in plans to ease stay-at-home restrictions, saying that New York would eventually screen 100,000 people a day.” However, there’s been a hang up. The increasing popularity and demand for rapid antibody test kits has led to a flood of inaccurate and non-validated test kits entering the market. To help prevent that, the US FDA also released new guidelines to increase oversight to prevent the entry of numerous flawed rapid antibody tests and to ensure accuracy. With testing demand only likely to pick up momentum, it’s creating opportunity for companies such as Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF), Laboratory Corp. of America Holdings (NYSE:LH), Abbott Laboratories (NYSE:ABT), Quest Diagnostics Inc. (NYSE:DGX), and Vir Biotechnology Inc. (NASDAQ:VIR). Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF) BREAKING NEWS: Blackhawk Growth Corp. just announced that after submitting its initial order on May 1, 2020 for 1,000 Innovita manufactured Covid-19 antibody testing kits, the kits arrived and were delivered to the healthcare clinic in Rocklin, California on May 6, 2020. These testing kits are being immediately distributed to healthcare professionals in the area. “This is the start we were hoping for” said Frederick Pels, CEO of Blackhawk Growth Corp. “Showing that we can deliver these kits in record time puts us vastly ahead of others in the space. The clinic is ecstatic, and we have begun negotiations on additional larger orders. A 5-day delivery time is phenomenal and I'm certain it will raise the attention of new buyers and assist us in our other ongoing negotiations. I look forward to keeping our shareholders updated as we continue to execute and do our part to flatten the curve.” “We are extremely pleased to have been able to fulfill this order in such an efficient and timely fashion” says James Saunders of Emergence Technology Pty. Ltd. “We pride ourselves in our ability to deliver for our partners and while everyone else on the market can’t get these kits for months, we were able to deliver them within a week. This accomplishment showcases our ability to leverage our relationship with the manufacturer to deliver antibody testing kits in the direst of times. The goal of this order was to prove that we are able to deliver these kits quicker than anyone else on the market and we look forward to delivering many more over the coming months.” Other related developments from around the markets include: Laboratory Corp. of America Holdings (NYSE:LH) announced that its COVID-19 Immunoglobulin G (IgG) antibody test is now available for individuals through LabCorp.com. With the addition of this latest offering, individuals have the ability to receive the COVID-19 IgG antibody test from their doctor, in person or through a telemedicine program, and now directly using LabCorp.com. LabCorp does not require upfront out-of-pocket costs for the IgG antibody test. If the individual uses LabCorp.com to get the test, there is a non-reimbursable fee of $10 paid to PWNHealth to cover the independent physician service costs. If the test is ordered through the individual’s doctor or healthcare provider, the $10 PWNHealth fee does not apply. “We are working as quickly as possible to develop and implement new solutions to combat COVID-19,” said Adam Schechter, president and CEO of LabCorp. “We continue to bring our deep research and scientific expertise to the market, and are now making it more convenient for people to access our tests through our wide network of physicians, hospitals and healthcare providers, and now through LabCorp.com.” Abbott Laboratories (NYSE:ABT) announced today new research, published in the Journal of Clinical Microbiology, which found that its SARS-CoV-2 IgG lab-based serology blood test had 99.9% specificity and 100% sensitivity for detecting the IgG antibody in patients 17 days or more after symptoms began. Independent research was conducted by University of Washington School of Medicine in Seattle. Antibody testing can tell if someone has been previously infected with the virus and may be recovering or has recovered from the infection, in both people with or without signs or symptoms. Large scale antibody testing is seen as an important next step to understanding and addressing the COVID-19 pandemic and is part of the Centers for Disease Control and Prevention's (CDC) surveillance strategy. Antibody tests will provide greater understanding of the virus, including how long antibodies stay in the body, how much of the population has been infected, and how this changes over time. "Health systems will play a critical role in large scale testing, and collaboration with leaders such as the University of Washington helps to ensure that our tests are performing at the highest standards when they are used in real-world settings," said Robert B. Ford, president and chief executive officer, Abbott. "We want to do our part in providing hospitals and reference labs around the world with access to reliable antibody testing." In April, Abbott announced the launch of its SARS-CoV-2 IgG antibody blood test as the company's third COVID-19 test to help combat the pandemic. Abbott significantly scaled up its manufacturing and has already shipped more than 10 million antibody tests for its ARCHITECT platform to hospital systems and reference labs in all 50 states in the U.S. and around the world. Quest Diagnostics Inc. (NYSE:DGX) announced that its 2020 Annual Meeting of Stockholders will now be held solely by remote communication through a live, online audio webcast. This decision was made as a result of the public health threat caused by the COVID-19 pandemic, mandated limits on public gatherings and to protect the health and safety of the company's stockholders and employees. The Annual Meeting will be held online at 10:30 a.m. Eastern Time on May 19, 2020. Stockholders will not be able to attend the Annual Meeting in person. Stockholders as of the close of business on March 20, 2020 (the "Record Date") will be able to participate in, vote at and ask questions during the Annual Meeting through the webcast. The items of business are the same as set forth in the meeting notice previously mailed or made available. Set forth below are instructions for stockholders to be admitted to, and participate in, the Annual Meeting. Vir Biotechnology Inc. (NASDAQ:VIR) announced that George Scangos, Ph.D., Chief Executive Officer will virtually present at the BofA Securities2020 Health Care Conference on Thursday, May 14TH at 12:40 pm PT/ 3:40 pm ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Blackhawk Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Blackhawk Growth Corp. We own ZERO shares of Blackhawk Growth Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@WallStreetNation.com
Accurate Antibody Testing is Necessary to Reopen the Global Economy May 11, 2020 - Baystreet.ca There’s sizable demand for COVID-19 antibody tests. While the World Health Organization says it’s still too early to tell if having antibodies makes people immune to catching COVID-19, politicians are clamoring for more testing. That’s because if enough people test positive without getting sick, says Fox 11 Los Angeles, “it’s a good indicator that restrictions can start being eased.” “The more testing, the more open the economy,” Gov. Andrew M. Cuomo of New York said, as quoted by the New York Times. “He has pushed for the production of antibody tests as a central cog in plans to ease stay-at-home restrictions, saying that New York would eventually screen 100,000 people a day.” However, there’s been a hang up. The increasing popularity and demand for rapid antibody test kits has led to a flood of inaccurate and non-validated test kits entering the market. To help prevent that, the US FDA also released new guidelines to increase oversight to prevent the entry of numerous flawed rapid antibody tests and to ensure accuracy. With testing demand only likely to pick up momentum, it’s creating opportunity for companies such as Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF), Laboratory Corp. of America Holdings (NYSE:LH), Abbott Laboratories (NYSE:ABT), Quest Diagnostics Inc. (NYSE:DGX), and Vir Biotechnology Inc. (NASDAQ:VIR). Blackhawk Growth Corp. (CSE:BLR)(OTC:BLRZF) BREAKING NEWS: Blackhawk Growth Corp. just announced that after submitting its initial order on May 1, 2020 for 1,000 Innovita manufactured Covid-19 antibody testing kits, the kits arrived and were delivered to the healthcare clinic in Rocklin, California on May 6, 2020. These testing kits are being immediately distributed to healthcare professionals in the area. “This is the start we were hoping for” said Frederick Pels, CEO of Blackhawk Growth Corp. “Showing that we can deliver these kits in record time puts us vastly ahead of others in the space. The clinic is ecstatic, and we have begun negotiations on additional larger orders. A 5-day delivery time is phenomenal and I'm certain it will raise the attention of new buyers and assist us in our other ongoing negotiations. I look forward to keeping our shareholders updated as we continue to execute and do our part to flatten the curve.” “We are extremely pleased to have been able to fulfill this order in such an efficient and timely fashion” says James Saunders of Emergence Technology Pty. Ltd. “We pride ourselves in our ability to deliver for our partners and while everyone else on the market can’t get these kits for months, we were able to deliver them within a week. This accomplishment showcases our ability to leverage our relationship with the manufacturer to deliver antibody testing kits in the direst of times. The goal of this order was to prove that we are able to deliver these kits quicker than anyone else on the market and we look forward to delivering many more over the coming months.” Other related developments from around the markets include: Laboratory Corp. of America Holdings (NYSE:LH) announced that its COVID-19 Immunoglobulin G (IgG) antibody test is now available for individuals through LabCorp.com. With the addition of this latest offering, individuals have the ability to receive the COVID-19 IgG antibody test from their doctor, in person or through a telemedicine program, and now directly using LabCorp.com. LabCorp does not require upfront out-of-pocket costs for the IgG antibody test. If the individual uses LabCorp.com to get the test, there is a non-reimbursable fee of $10 paid to PWNHealth to cover the independent physician service costs. If the test is ordered through the individual’s doctor or healthcare provider, the $10 PWNHealth fee does not apply. “We are working as quickly as possible to develop and implement new solutions to combat COVID-19,” said Adam Schechter, president and CEO of LabCorp. “We continue to bring our deep research and scientific expertise to the market, and are now making it more convenient for people to access our tests through our wide network of physicians, hospitals and healthcare providers, and now through LabCorp.com.” Abbott Laboratories (NYSE:ABT) announced today new research, published in the Journal of Clinical Microbiology, which found that its SARS-CoV-2 IgG lab-based serology blood test had 99.9% specificity and 100% sensitivity for detecting the IgG antibody in patients 17 days or more after symptoms began. Independent research was conducted by University of Washington School of Medicine in Seattle. Antibody testing can tell if someone has been previously infected with the virus and may be recovering or has recovered from the infection, in both people with or without signs or symptoms. Large scale antibody testing is seen as an important next step to understanding and addressing the COVID-19 pandemic and is part of the Centers for Disease Control and Prevention's (CDC) surveillance strategy. Antibody tests will provide greater understanding of the virus, including how long antibodies stay in the body, how much of the population has been infected, and how this changes over time. "Health systems will play a critical role in large scale testing, and collaboration with leaders such as the University of Washington helps to ensure that our tests are performing at the highest standards when they are used in real-world settings," said Robert B. Ford, president and chief executive officer, Abbott. "We want to do our part in providing hospitals and reference labs around the world with access to reliable antibody testing." In April, Abbott announced the launch of its SARS-CoV-2 IgG antibody blood test as the company's third COVID-19 test to help combat the pandemic. Abbott significantly scaled up its manufacturing and has already shipped more than 10 million antibody tests for its ARCHITECT platform to hospital systems and reference labs in all 50 states in the U.S. and around the world. Quest Diagnostics Inc. (NYSE:DGX) announced that its 2020 Annual Meeting of Stockholders will now be held solely by remote communication through a live, online audio webcast. This decision was made as a result of the public health threat caused by the COVID-19 pandemic, mandated limits on public gatherings and to protect the health and safety of the company's stockholders and employees. The Annual Meeting will be held online at 10:30 a.m. Eastern Time on May 19, 2020. Stockholders will not be able to attend the Annual Meeting in person. Stockholders as of the close of business on March 20, 2020 (the "Record Date") will be able to participate in, vote at and ask questions during the Annual Meeting through the webcast. The items of business are the same as set forth in the meeting notice previously mailed or made available. Set forth below are instructions for stockholders to be admitted to, and participate in, the Annual Meeting. Vir Biotechnology Inc. (NASDAQ:VIR) announced that George Scangos, Ph.D., Chief Executive Officer will virtually present at the BofA Securities2020 Health Care Conference on Thursday, May 14TH at 12:40 pm PT/ 3:40 pm ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Blackhawk Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Blackhawk Growth Corp. We own ZERO shares of Blackhawk Growth Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@WallStreetNation.com